Form 4: Lantern Pharma Director Granted 42,307 Stock Options

Lantern Pharma Inc. Director Vijay Chandru was granted 42,307 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Summary

• Vijay Chandru, a Director of Lantern Pharma Inc. (LTRN), was granted a total of 42,307 stock options.
• One grant consists of 25,000 stock options with an exercise price of $3.49 per share, vesting in equal monthly increments over a 24-month period commencing February 9, 2026.
• A second grant consists of 17,307 stock options with an exercise price of $3.49 per share, vesting in equal monthly increments over a 12-month period commencing February 9, 2026.
• Both sets of options were granted on January 9, 2026, and expire on January 8, 2036.
• The options were granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of an insider equity grant. While not directly indicative of operational performance, the grant of options to a director is generally viewed as a neutral to slightly positive event, as it aligns management's interests with shareholders for future growth.

Positives

• The grant of stock options to a director aligns management's financial interests with those of shareholders, potentially incentivizing long-term company performance.
• The options were granted under an existing, approved stock incentive plan, indicating a structured approach to executive compensation.

Future Outlook

The vesting schedules for the granted options extend over 12 and 24 months, commencing February 9, 2026, indicating a long-term incentive structure for the director.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industry for compensating directors and executives, aiming to align their incentives with the company's long-term success and shareholder value creation. This is a standard mechanism for equity-based compensation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation within the biotechnology sector, designed to incentivize long-term performance and align interests with shareholders.
• Specific comparable companies, projects, or results are not provided within this Form 4 filing, as it is a transactional disclosure rather than a performance report.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive for shareholders, as it aligns the director's financial interests with the company's long-term stock performance.
• Management/Director: Vijay Chandru receives a significant equity incentive, which will vest over time, providing a direct financial stake in the company's future success.

Next Steps

• The stock options will begin to vest in equal monthly increments starting February 9, 2026, over periods of 12 and 24 months.

Key Dates

Keywords

Lantern Pharma, LTRN, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Form 4, Vijay Chandru